• 1
    Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:12101215.
  • 2
    Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87:198205.
  • 3
    Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524530.
  • 4
    Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:14521460.
  • 5
    Vokes EE, Herndon JE 2nd, Kelley MJ, et al;Cancer and Leukemia Group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007;25:16981704.
  • 6
    Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379386.
  • 7
    Bradley J, Paulus R, Komaki R, et al. A randomized phase III comparison of standard-dose (60 gy) versus high-dose (74 gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: results on radiation dose in RTOG 0617. J Clin Oncol. 2013;31:7501.
  • 8
    Chen AB, Neville BA, Sher DJ, Chen K, Schrag D. Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol. 2011;29:23052311.
  • 9
    American College of Surgeons Cancer Programs. National Cancer Database. Access date.
  • 10
    Mallin K, Palis BE, Watroba N, et al. Completeness of American Cancer Registry Treatment Data: implications for quality of care research. J Am Coll Surg. 2013;216:428437.
  • 11
    Coca-Perraillon M. Local and global optimal propensity score matching. In: Proceedings of the SAS Global Forum 2007; April 16–19, 2007; Orlando, FL.
  • 12
    Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:21812190.
  • 13
    Auperin A, Le Pechoux C, Pignon JP, et al;Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol. 2006;17:473483.
  • 14
    Movsas B, Hu C, Sloan J, et al. Quality of life (QOL) analysis of the randomized radiation (RT) dose-escalation NSCLC trial (RTOG 0617): the rest of the story. Int J Radiat Oncol Biol Phys. 2013;87:S1.
  • 15
    Komaki R, Khalid N, Langer CJ, et al. Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey. Int J Radiat Oncol Biol Phys. 2013;85:10821089.
  • 16
    Erhunmwunsee L, Joshi MB, Conlon DH, Harpole DH Jr. Neighborhood-level socioeconomic determinants impact outcomes in nonsmall cell lung cancer patients in the southeastern United States. Cancer. 2012;118:51175123.
  • 17
    Niu X, Roche LM, Pawlish KS, Henry KA. Cancer survival disparities by health insurance status. Cancer Med. 2013;2:403411.
  • 18
    Slatore CG, Au DH, Gould MK,American Thoracic Society Disparities in Healthcare Group. An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes. Am J Respir Crit Care Med. 2010;182:11951205.
  • 19
    Saeed AM, Toonkel R, Glassberg MK, et al. The influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival: an analysis of the Survival, Epidemiology, and End Results database. Cancer. 2012;118:44954501.
  • 20
    Sher DJ, Liptay MJ, Fidler MJ. Patient and institutional predictors of trimodality therapy for stage III non-small cell lung cancer (NSCLC) in the national cancer database. Int J Radiat Oncol Biol Phys. 2013;87:S180.
  • 21
    Chen AY, Fedewa S, Pavluck A, Ward EM. Improved survival is associated with treatment at high-volume teaching facilities for patients with advanced stage laryngeal cancer. Cancer. 2010;116:47444752.